A

s physicians increasingly rely on treatment guidelines issued by medical societies and government agencies, researchers raise concerns that drug makers may subtly influence the proceedings through various financial relationships and they recommend stronger actions for disclosing potential conflicts of interest.

The industry influence can take different forms, however, according to the research, which was published in a pair of papers on Tuesday in JAMA Internal Medicine.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories